Cross-Sector entity
Every one of those 2 sits in a single category, clinical-trial. Massachusetts General Hospital is most often covered alongside Dr. Marc Siegel, which appears in 1 of these 2 stories. Across a 174-day span, the pace is roughly 0.1 stories per week.
2 verified stories tracked
Last mentioned: 6d ago
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, clinical-trial. Massachusetts General Hospital is most often covered alongside Dr. Marc Siegel, which appears in 1 of these 2 stories. Across a 174-day span, the pace is roughly 0.1 stories per week. We currently track 2 Cross-Sector stories that mention Massachusetts General Hospital, published between February 26, 2026 and August 18, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Massachusetts General Hospital. Shared-story counts are live from our verified record — not editorial picks.
Interim Analysis
Expected window for preliminary safety and biomarker data review by the trial committee.
Dosing Initiation
First patient dosed with NUZ-001 in the multi-center Phase 2/3 study.
Trial Selection
NUZ-001 selected as a new regimen for the HEALEY ALS Platform Trial.
Diagnosis-to-treatment intervals grew for six early-stage cancers from 2012–2023, with lung (+12 days) and stomach (+14 days) leading. For biopharma, longer real-world waits threaten neoadjuvant therapy windows and perioperative trial design.
Source: fox7austin.com · fox32chicago.com
Neurizon has officially commenced patient dosing for NUZ-001 in the HEALEY ALS Platform Trial, a multi-center study led by Massachusetts General Hospital. This milestone marks a critical transition for the biotech as it seeks to validate its mTOR inhibitor as a disease-modifying therapy for Amyotrophic Lateral Sclerosis.
Source: sydneysun.com · malaysiasun.com
